Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2024 16:06 ET | Source: Biogen Inc.

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its...
December 15, 2023 09:05 ET | Source: Biogen Inc.

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...